Processa Pharmaceuticals, Inc. Proceeds from Secured Notes Payable
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Secured Notes Payable of $327.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuredNotesPayable · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for the quarter ending 2017-09-30 was $252.00K.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for the quarter ending 2016-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for fiscal 2016 was $15.00K, a 98.01% decline from fiscal 2015.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for fiscal 2015 was $753.00K.
- Processa Pharmaceuticals, Inc. proceeds from secured notes payable for fiscal 2013 was $1.00M.
| Period end | Proceeds from Secured Notes Payable 0 month | Proceeds from Secured Notes Payable 1 month | Proceeds from Secured Notes Payable 3 month | Proceeds from Secured Notes Payable 6 month | Proceeds from Secured Notes Payable 6 month as first filed | Proceeds from Secured Notes Payable 9 month | Proceeds from Secured Notes Payable 12 month | Proceeds from Secured Notes Payable 33 month | Proceeds from Secured Notes Payable 36 month |
|---|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | $252.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $327.00K 10-Q · filed 2017-11-20 | |||||||
| 2017-06-30 | $75.00K 10-Q · filed 2017-10-04 | ||||||||
| 2017-06-09 | $75.00K 10-Q · filed 2017-09-08 | ||||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $0.00 derived: sum of 2 quarters · filed 2017-11-20 | $0.00 derived: sum of 3 quarters · filed 2017-11-20 | $15.00K 10-K · filed 2017-09-25 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $0.00 derived: sum of 2 quarters · filed 2017-11-20 | $15.00K 10-Q · filed 2017-11-20 | $15.00K derived: sum of 4 quarters · filed 2017-11-20 | |||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | $15.00K 10-Q · filed 2017-10-04 | $15.00K derived: sum of 3 quarters · filed 2017-10-04 | $39.64K derived: sum of 4 quarters · filed 2017-10-04 | |||||
| 2016-03-31 | $15.00K 10-Q · filed 2017-10-04 | $15.00K derived: sum of 2 quarters · filed 2017-10-04 | $39.64K derived: sum of 3 quarters · filed 2017-10-04 | $318.00K derived: sum of 4 quarters · filed 2017-10-04 | |||||
| 2016-03-23 | $15.00K 10-K · filed 2017-06-19 | ||||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $24.64K derived: sum of 2 quarters · filed 2017-09-25 | $303.00K derived: sum of 3 quarters · filed 2017-09-25 | $753.00K 10-K · filed 2017-09-25 | |||||
| 2015-09-30 | $24.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $303.00K derived: sum of 2 quarters · filed 2017-09-08 | $753.00K 10-Q · filed 2017-09-08 | ||||||
| 2015-06-30 | $278.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | $728.36K 10-Q · filed 2017-08-30 | $714.00K 10-Q · filed 2015-08-19 | ||||||
| 2015-03-31 | $450.00K 10-Q · filed 2017-08-07 | ||||||||
| 2014-03-31 | $0.00 derived: 10-Q 36 month − 10-K 33 month · filed 2014-05-14 | $0.00 derived: sum of 2 quarters · filed 2015-04-14 | $9.91K derived: sum of 3 quarters · filed 2015-04-14 | $2.50M 10-Q · filed 2014-05-14 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $9.91K derived: sum of 2 quarters · filed 2015-04-14 | $1.00M 10-K · filed 2015-04-14 | $2.50M 10-K · filed 2014-03-27 | |||||
| 2013-09-30 | $9.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.00M 10-Q · filed 2014-11-13 | |||||||
| 2013-06-30 | $990.09K 10-Q · filed 2014-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |